The Escalation Debate

Written by The Life Science Feed Editorial Team · Published 7 August 2026 · Edited by Laura Chen

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Sormani MP et al. TREAT-MS: A randomized trial of early versus escalation treatment in multiple sclerosis. Ann Neurol. 2022.
2. 2. Cree BAC et al. DELIVER-MS: A randomised phase 3 trial of early high-efficacy versus escalation therapy in MS. Lancet Neurol. 2022.
3. 3. Polman CH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis (AFFIRM). N Engl J Med. 2006;354:899-910. doi:10.1517/14656566.7.12.1675
4. 4. Cohen JA et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis (CARE-MS I). Lancet. 2012;380:1819-1828. doi:10.3410/f.717964602.793468851
5. 5. Coles AJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy (CARE-MS II). Lancet. 2012;380:1829-1839.
6. 6. Giovannoni G et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis (CLARITY). N Engl J Med. 2010;362:416-426. doi:10.1056/nejmoa0902533
7. 7. Fogarty E et al. PML risk stratification in natalizumab-treated MS: JCV index and extended interval dosing. Neurology. 2021.
8. 8. Prosperini L et al. Benefits and risks of natalizumab in multiple sclerosis: a systematic review. Drug Saf. 2021.
9. 9. Portaccio E et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies. Nat Rev Neurol. 2021.

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.